Journals / Anadolu Kardiyoloji Dergisi / 2002 / Cilt: 2 - Sayı: 3

Is intermittent dobutamine treatment beneficial in patients with dilated cardiomyopathy?

Dilate kardiyomiyopatili hastalarda aralıklı dobutamin tedavisi faydalı mıdır?

Pages
220–223
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: After the first treatment, left ventricular ejection fraction (LVEF), cardiac output, cardiac index (CI), pulmonary wedge pressure and life quality improved significantly (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Dobutamine is a sympathomimetic drug, which can be used in patients with dilated cardiomyopathy (DCM).
📊
Key Findings & Data:In addition to traditional treatment, dobutamine (1-2 $mu$g/kg/min infusion increasing up to 10 $mu$g/kg/min for 3 days) was administered, and repeated at the 1st, 2nd and 3rd months.
💡
Conclusion & Impact:Results: After the first treatment, left ventricular ejection fraction (LVEF), cardiac output, cardiac index (CI), pulmonary wedge pressure and life quality improved significantly (p
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Dobutamine is a sympathomimetic drug, which can be used in patients with dilated cardiomyopathy (DCM). We investigated the effects of intermittent dobutamine use on cardiac parameters and quality of life in patients with DCM. Methods: Twelve patients with ischemic and idiopathic DCM, refractory to conventional therapy, have been included in the study. In addition to traditional treatment, dobutamine (1-2 $mu$g/kg/min infusion increasing up to 10 $mu$g/kg/min for 3 days) was administered, and repeated at the 1st, 2nd and 3rd months. The patients were evaluated 3 times, before and immediately after the first treatment and after the treatment on the third month, using echocardiography, exercise stress testing, ambulatory ECG, right ventricular catheterization, cardiac enzymes (creatine kinase MB isoenzyme - CK-MB, troponin-T) and the Minnesota Living with Heart Failure Questionnaire for quality of life. Results: After the first treatment, left ventricular ejection fraction (LVEF), cardiac output, cardiac index (CI), pulmonary wedge pressure and life quality improved significantly (p

Özet

Amaç: Dobutamin, tedaviye dirençli dilate kardiyomyopati (DKMP) olgularında kullanılabilen sempatomimetik bir ilaçtır. Aralıklı dobutamin uygulamasının DKMP'li olgularda kardiyak parametreler ve yaşam kalitesi üzerine etkilerini araştırdık. Yöntem: Çalışmaya iskemik ve idiyopatik DKMP'li, konvansiyonel tedaviye dirençli 12 hasta alındı. Dobutamin, 3 gün süreyle ve konvansiyonel kalp yetersizliği tedavisine ek olarak uygulandı; 1-2 $mu$g/kg/dk'dan başlanarak 10 $mu$g/kg/dk'ya kadar artırıldı. Aynı tedavi protokolü 1, 2 ve 3. aylarda da yenilendi. Hastalar ilk tedavinin hemen öncesinde, sonrasında ve 3. aydan sonra, ekokardiyografi, efor testi, 12 derivasyonlu ambulatuar EKG izlemi, sağ kalp kateterizasyonu ile değerlendirildi. Minnesota Üniversitesi Kalp Yetersizlikli Hastalarda Yaşam Kalitesini Değerlendirme soruları ile yaşam kalitesi skorlaması (YKS) yapıldı. Aynı dönemlerde kreatin-kinaz MB formu (CK-MB) ve troponin-T düzeyleri ölçüldü. Bulgular: İlk tedaviden sonra, sol ventrikül ejeksiyon fraksiyonu (EF), kardiyak output (KO), kardiyak indeks (Kİ), pulmoner kapiller tıkalı basınç (PKTB) ve yaşam kalitesinde anlamlı iyileşmeler elde edildi (p

🔖

Cite This Article

TOPSAKAL, R., ERYOL, N. K., ÇETİN, S., BAŞAR, E., ERGİN, A., ABACI, A., GÜVEN, M. (2022). Is intermittent dobutamine treatment beneficial in patients with dilated cardiomyopathy?. Anadolu Kardiyoloji Dergisi, Cilt: 2 - Sayı: 3, 220–223. https://ajindex.com/articles/437550

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bristow MR, Bohlmeyer TJ, Gilbert EM. Dilated cardiomyopathy. In: Alexander RW, Schlant RC, Fuster V, editors. Hurst’s The Heart. New York: McGraw Hill
  2. p. 2039-2055. 2.Wyne J, Braunwald E. The cardiomyopathies and myocarditis. In: Braunwald E, Zipes DP, Libby P, editors. Heart Disease. Philadelphia:W.B. Saunders Company
  3. p. 1404-1434. 3.Unverferth DV, Magorien RD, Lewis RP, Leier CV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980
  4. Lewin RF, Davidson E, Zafir N, et al. Short and long term dobutamine treatment in chronic heart failure. Clin Cardiol 1987
  5. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996
  6. O’Connor CM, Gattis WA, Utersky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999
  7. Leier CV: Current status of non-digitalis positive inotropic drugs. Am J Cardiol 1992
  8. 120G. 8.Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978
  9. Taylor R, Waggoner AD. Doppler assessment of left ventricular diastolic function: a review. J Am Soc Echocardiogr 1992
  10. Braunwald E, Colucci WS, Grossman W. Clinical aspects of heart failure: High-output heart failure
  11. pulmonary edema In:Braunwald E, Zipes DP, Libby P, editors. Heart Disease. Philadelphia: W.B. Saunders company, 1997. p:454. 11.Vaage-Nilsen M, Rasmussen V, Sørum C, Jensen G. ST-segment deviation during 24-hour ambulatory electrocardiographic monitoring and exercise stress test in healty male subjects 51 to 75 years of age: The Copenhagen City, heart Study. Am Heart J 1999
  12. Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: A new synthetic cardioactive amine. N Engl J Med. 1979
  13. Ramahi TM, Longo MD, Cadariu AR, et al. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with ischaemic cardiomyopathy. Eur Heart J 2001
  14. Cheung PY, Barrington KJ, Bigam D. The hemodynamic effects of dobutamine infusion in the chronically instrumented newbor